Clinical, Genetic, MR Spectroscopy characteristics and Response to Flunarizine in Episodic Ataxia Type 2: The Sheffield Ataxia Cohort

Episodic ataxia type 2 (EA2) is an autosomal-dominant calcium channelopathy caused by pathogenic mutations in the CACNA1A gene, characterized by episodic cerebellar symptoms and marked phenotypic heterogeneity. Data on real-world clinical features and treatment responses, particularly in the era of major genetic advances, remain limited. This is a retrospective observational single-centre case series of 58 individuals from 38 families with genetically confirmed EA2. Clinical, demographic, genetic, and treatment data were extracted from medical records using a standardized Excel-based data collection tool. Symptom patterns with associated neurological features, genetic characteristics, and treatment responses were analyzed descriptively. Paired MRI imaging including MR spectroscopy (MRS) of the cerebellum at baseline and follow up data, and medication efficacy were assessed using patient-reported benefit, and statistical analysis was performed using Wilcoxon signed rank test and Exact binomial testing respectively. The mean age at diagnosis was 35.2 ± 21.5 years, and a positive family history was identified in 48 patients (82.70%). The most frequent clinical manifestations were gait instability (87.93%), dysarthria (39.66%), headache (58.62%) and isolated dizziness (48.28%). Episodic symptoms predominated, with 33 patients (56.89%) experiencing discrete attacks. Amongst those with episodic symptoms, weekly attacks were the most common (42.4%), while 17 patients (29.31%) exhibited a non-episodic course with persistent symptoms. Interictal oculomotor abnormalities, including nystagmus, were noted in some individuals. Paired longitudinal MRS analyses for both vermis (W = 118.0, p = 0.67) and hemisphere (W = 122.0, p = 0.39) revealed no significant change over time. Flunarizine showed the highest rate of therapeutic benefit, with 76.5% of treated patients reporting improvement ( p = 0.04), whereas other treatments demonstrated variable but non-significant effects. This study highlights the clinical heterogeneity and neuroimaging (MRS) insight of EA2 underscoring the predominance of episodic manifestations, while also recognizing a subset with non-episodic symptoms. Flunarizine appears to be an effective, accessible therapeutic option for reducing attack frequency and duration in EA2, though further studies are required to compare efficacy with alternative therapeutic options such as acetazolamide.

Authors

Institutions

Publication Details

Journal
The Cerebellum
Published
2026-11-21
DOI
https://doi.org/10.1007/s12311-026-02122-y
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical, Genetic, MR Spectroscopy characteristics and Response to Flunarizine in Episodic Ataxia Type 2: The Sheffield Ataxia Cohort

Priya Devi Shanmugarajah, Vikrant Devgire, Nigel Hoggard, Marios Hadjivassiliou et al.
The Cerebellum
Migraine and Headache Studies
article

Clinical, Genetic, MR Spectroscopy characteristics and Response to Flunarizine in Episodic Ataxia Type 2: The Sheffield Ataxia Cohort

Priya Devi Shanmugarajah, Vikrant Devgire, Nigel Hoggard, Marios Hadjivassiliou, Ikechukwu Chukwuocha, Nick J. Beauchamp, Emma Foster
article en

Abstract

Episodic ataxia type 2 (EA2) is an autosomal-dominant calcium channelopathy caused by pathogenic mutations in the CACNA1A gene, characterized by episodic cerebellar symptoms and marked phenotypic heterogeneity. Data on real-world clinical features and treatment responses, particularly in the era of major genetic advances, remain limited. This is a retrospective observational single-centre case series of 58 individuals from 38 families with genetically confirmed EA2. Clinical, demographic, genetic, and treatment data were extracted from medical records using a standardized Excel-based data collection tool. Symptom patterns with associated neurological features, genetic characteristics, and treatment responses were analyzed descriptively. Paired MRI imaging including MR spectroscopy (MRS) of the cerebellum at baseline and follow up data, and medication efficacy were assessed using patient-reported benefit, and statistical analysis was performed using Wilcoxon signed rank test and Exact binomial testing respectively. The mean age at diagnosis was 35.2 ± 21.5 years, and a positive family history was identified in 48 patients (82.70%). The most frequent clinical manifestations were gait instability (87.93%), dysarthria (39.66%), headache (58.62%) and isolated dizziness (48.28%). Episodic symptoms predominated, with 33 patients (56.89%) experiencing discrete attacks. Amongst those with episodic symptoms, weekly attacks were the most common (42.4%), while 17 patients (29.31%) exhibited a non-episodic course with persistent symptoms. Interictal oculomotor abnormalities, including nystagmus, were noted in some individuals. Paired longitudinal MRS analyses for both vermis (W = 118.0, p = 0.67) and hemisphere (W = 122.0, p = 0.39) revealed no significant change over time. Flunarizine showed the highest rate of therapeutic benefit, with 76.5% of treated patients reporting improvement ( p = 0.04), whereas other treatments demonstrated variable but non-significant effects. This study highlights the clinical heterogeneity and neuroimaging (MRS) insight of EA2 underscoring the predominance of episodic manifestations, while also recognizing a subset with non-episodic symptoms. Flunarizine appears to be an effective, accessible therapeutic option for reducing attack frequency and duration in EA2, though further studies are required to compare efficacy with alternative therapeutic options such as acetazolamide.

The CerebellumVol. 25(6)
Royal Hallamshire Hospital (GB), Sheffield Children's NHS Foundation Trust (GB), University of Sheffield (GB)
Migraine and Headache Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon